Evidence supporting the use of: Haematococcus pluvialis
For the health condition: Cataracts
Synopsis
Source of validity: Scientific
Rating (out of 5): 2
Haematococcus pluvialis is a microalga best known for its high content of astaxanthin, a potent antioxidant carotenoid. The use of Haematococcus pluvialis or its extract (astaxanthin) to support or treat cataracts is primarily based on its antioxidant properties, as oxidative stress is a key factor in cataract formation. Several preclinical studies (in vitro and animal models) have shown that astaxanthin can protect lens proteins and epithelial cells from oxidative damage, potentially slowing the progression of cataract development. For example, animal studies have demonstrated that astaxanthin supplementation can reduce lens opacity and oxidative biomarkers in models of induced cataract.
However, direct clinical evidence in humans is limited. There are no large-scale randomized controlled trials specifically using Haematococcus pluvialis or astaxanthin for cataract prevention or treatment in humans. Some small clinical trials and observational studies suggest that diets rich in carotenoids (including astaxanthin) may be associated with a lower risk of cataract, but these findings are not definitive for astaxanthin alone. Thus, while there is plausible mechanistic and early preclinical support, robust human data is lacking, resulting in a moderate-low evidence rating.
Other health conditions supported by Haematococcus pluvialis
Aging (prevention)Arthritis
Cancer (natural therapy for)
Cancer (prevention)
Cancer Treatment (reducing side effects)
Cardiovascular Disease
Cataracts
Chemotherapy (reducing side effects)
Cholesterol (high)
Diabetes
Free Radical Damage
Inflammation
Parkinson's Disease
Skin Care (general)
Wrinkles